222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details
臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-IPR-16008527 | 2016-06-01 | 2016-05-24 | Rituximab in the treatment of refractory membranous nephropathy: a multicenter, randomized, controlled clinical study | Rituximab in the treatment of resistant membranous nephropathy: a multicenter, randomized, controlled clinical study | Membranous nephropathy | CsA group:oral CsA and glucosteroid;RTX group:intravenous RTX;CTX:Intravenous cyclophosphamide and glucosteroid; | Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine | NULL | Completed | 18 | 70 | Both | CsA group:60;RTX group:60;CTX:60; | Phase 4 | China |